Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 57

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 57
---
 the costs we may have incurred in the development of
particular products and may never achieve profitable royalty or licensing revenues from that product.

The pharmaceutical and biotechnology industries are highly competitive.

The development and commercialization
of new drug products is highly competitive. Our business faces competition from a range of major and specialty pharmaceutical and biotechnology
companies worldwide with respect to our product candidates, and will face competition in the future with respect to any product candidates
that we may seek to develop or commercialize.

There are a number of pharmaceutical
and biotechnology companies that currently market and sell products or are pursuing development of products that could compete with our
product candidates. With respect to eRapa, there are no currently approved products with a FAP indication, though certain non-steroidal
anti-inflammatory drugs may be prescribed off label. Panbela Therapeutics, Inc. and Recursion Pharmaceuticals, Inc. are developing products
for FAP. With respect to tolimidone, teplizumab, the first disease-modifying treatment of Type 1 diabetes, or T1D, has been approved for
the delay of Stage 3 T1D and a number of companies are researching potentially disease-modifying approaches to T1D including stem cell
therapies by Vertex Pharmaceuticals, Inc. and CRISPR Therapeutics AG and SAB Biotherapeutics, Inc. is developing an immunotherapeutic.
In addition, the JDRF T1D Fund has invested in approximately 30 private companies working on a variety of approaches to the treatment
of T1D. With respect to MTX110, there are a number of companies researching potential therapeutic treatments of GBM including CNS Pharmaceuticals,
Inc. and Plus Therapeutics, Inc. Chimerix Inc. is among a number of companies developing a product for DMG.

Some of these competitive
products and therapies are based on scientific approaches that are the same or similar to our approach, and others are based on entirely
different approaches. Potential competitors also include academic institutions, government agencies and other public and private research
organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing
and commercialization.

Our competitors in the biotechnology
and pharmaceutical industries may have superior research and development capabilities, products, manufacturing capability or sales and
marketing expertise. Many of our competitors may have significantly greater financial and human resources and may have more experience
in research and development.

As a result of these factors,
our competitors may obtain regulatory approval of their products